HUMIRA Approved In Europe For Severe Active Pediatric Crohn's Disease
Tuesday, November 27, 2012 - 09:01
in Health & Medicine
The European Commission has approved Abbott's HUMIRA® (adalimumab) for the treatment of pediatric patients aged 6 to 17 years with severe active Crohn's disease (CD) who failed, are intolerant to, or have contraindications to conventional therapy. read more